KNCV Tuberculosis Foundation, The Hague, the Netherlands.
Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Euro Surveill. 2022 Mar;27(12). doi: 10.2807/1560-7917.ES.2022.27.12.2100183.
BackgroundNot all treated tuberculosis (TB) patients achieve long-term recovery and reactivation rates reflect effectiveness of TB treatment.AimWe aimed to estimate rates and risk factors of TB reactivation and reinfection in patients treated in the Netherlands, after completed or interrupted treatment.MethodsRetrospective cohort study of TB patients with available DNA fingerprint data, registered in the Netherlands Tuberculosis register (NTR) between 1993 and 2016. Reactivation was defined as an identical, and reinfection as a non-identical strain in sequential episodes.ResultsReactivation rate was 55/100,000 person-years (py) for patients who completed, and 318/100,000 py for patients who interrupted treatment. The risk of reactivation was highest in the first 5 years after treatment in both groups. The incidence rate of reactivation was 228/100,000 py in the first 2 years and 57/100,000 py 2-5 years after completed treatment. The overall rate of reinfection was 16/100,000 py. Among those who completed treatment, patients with male sex, mono or poly rifampicin-resistant TB and a previous TB episode had significantly higher risk of reactivation. Extrapulmonary TB was associated with a lower risk. Among patients who interrupted treatment, directly observed treatment (DOT) and being an undocumented migrant or people experiencing homelessness were associated with a higher risk of reactivation.ConclusionsBoth patients who completed or interrupted TB treatment should be considered as risk groups for reactivation for at least 2-5 years after treatment. They patients should be monitored and guidelines should be in place to enhance early detection of recurrent TB.
并非所有接受治疗的结核病(TB)患者都能实现长期康复,再激活率反映了 TB 治疗的效果。
我们旨在评估在荷兰完成或中断治疗的 TB 患者中,TB 再激活和再感染的发生率和危险因素。
这是一项回顾性队列研究,纳入了在 1993 年至 2016 年间在荷兰结核病登记处(NTR)注册、且具有可用 DNA 指纹数据的 TB 患者。再激活定义为连续发病时相同的菌株,再感染定义为非相同的菌株。
完成治疗的患者再激活率为 55/100000 人年(py),中断治疗的患者为 318/100000 py。两组患者的再激活风险在治疗后 5 年内最高。完成治疗后前 2 年的再激活发生率为 228/100000 py,2-5 年为 57/100000 py。再感染的总发生率为 16/100000 py。在完成治疗的患者中,男性、单或多利福平耐药性 TB 以及既往 TB 发作与再激活风险显著增加相关。肺外 TB 与较低的风险相关。在中断治疗的患者中,直接观察治疗(DOT)和无证件移民或无家可归者与再激活风险增加相关。
完成或中断 TB 治疗的患者都应被视为治疗后至少 2-5 年内再激活的风险群体。应监测这些患者并制定指南,以增强对复发性 TB 的早期检测。